000 02081cam  22003378a 4500
0019.830850
003CaOODSP
00520221107145623
007cr |||||||||||
008170119s2017    onc     o    f000 0 eng d
020 |a978-0-660-07290-6
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-157/1-2017E-PDF
24500|aUpdated recommendations on human papillomavirus (HPV) vaccines |h[electronic resource] : |b9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations.
2461 |iAt head of title: |aAdvisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI)
24630|a9-valent HPV vaccine 2-dose immunization schedule
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2017.
300 |a29 p.
500 |aIssued also in HTML format.
500 |aIssued also in French under title: Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : calendrier de vaccination du vaccin nonavalent contre le VPH à deux doses et utilisation des vaccins anti-VPH chez les populations immunodéprimées.
504 |aIncludes bibliographical references.
520 |a"Human papillomavirus (HPV) infections are the most common sexually transmitted infections. There are over 100 types of HPV, and they are broadly classified into high and low risk types"--Summary, p. 3.
69207|2gccst|aSexually transmitted diseases
69207|2gccst|aImmunization
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tRecommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) |w(CaOODSP)9.830853
85640|qPDF|s332 KB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-157-1-2017-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/updated-recommendations-human-papillomavirus-immunization-schedule-immunocompromised-populations.html